Cantor Fitzgerald Kept Reata Pharmaceuticals (RETA) As Buy; Has Price Target Of $100; Autoweb (AUTO) Shorts Up By 7.74%

Autoweb Inc (NASDAQ:AUTO) had an increase of 7.74% in short interest. AUTO’s SI was 664,200 shares in February as released by FINRA. Its up 7.74% from 616,500 shares previously. With 28,800 avg volume, 23 days are for Autoweb Inc (NASDAQ:AUTO)’s short sellers to cover AUTO’s short positions. The SI to Autoweb Inc’s float is 6.63%. The stock increased 0.91% or $0.0309 during the last trading session, reaching $3.4309. About 4,977 shares traded. AutoWeb, Inc. (NASDAQ:AUTO) has declined 77.89% since February 20, 2018 and is downtrending. It has underperformed by 77.89% the S&P500. Some Historical AUTO News: 08/03/2018 – AUTOWEB – CO WAS UNABLE TO FULLY MEET DEMAND FOR LEADS AND CLICKS IN QTR DUE TO HIGHER TRAFFIC ACQUISITION COSTS; 08/03/2018 – AUTOWEB INC – WESLEY OZIMA WILL BE NAMED INTERIM CFO; 08/03/2018 AutoWeb Announces Executive Management Succession Process; 08/03/2018 – AUTOWEB INC – KIMBERLY BOREN WILL BE STEPPING DOWN AS CFO; 16/03/2018 – Glancy Prongay & Murray LLP Announces Investigation on Behalf of AutoWeb, Inc. Investors (AUTO); 12/04/2018 – AUTOWEB INC – ROWE SUCCEEDING JEFFREY COATS; 12/04/2018 – AutoWeb Appoints Industry Veteran Jared Rowe to President and Chief Executive Officer; 15/03/2018 – PITON CAPITAL PARTNERS LLC REPORTS 5.3 PCT PASSIVE STAKE IN AUTOWEB INC AS OF MARCH 12, 2018 – SEC FILING; 28/03/2018 – AUTOWEB – ON MARCH 22, CO WAS TERMINATING LOAN AGREEMENT WITH UNION BANK, WHICH WAS INITIALLY ENTERED INTO ON FEBRUARY 26, 2013; 08/03/2018 – AUTOWEB INC – CEO JEFF COATS TO STEP DOWN

In a note revealed to clients and investors on today, Cantor Fitzgerald reaffirmed their Buy rating on Reata Pharmaceuticals (RETA)‘s stock. The price target indicates a potential upside of 13.55% from firm’s last price.

Analysts await Reata Pharmaceuticals, Inc. (NASDAQ:RETA) to report earnings on March, 1. They expect $-1.02 EPS, down 59.38% or $0.38 from last year’s $-0.64 per share. After $-1.07 actual EPS reported by Reata Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -4.67% EPS growth.

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company has market cap of $2.62 billion. The firm is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease. It currently has negative earnings. It is also developing omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia.

More notable recent Reata Pharmaceuticals, Inc. (NASDAQ:RETA) news were published by: which released: “Reata Announces Positive Phase 2 Data for Bardoxolone Methyl in Patients with Focal Segmental Glomerulosclerosis and in Patients From All Four Cohorts of PHOENIX – Nasdaq” on February 20, 2019, also with their article: “Analysis: Positioning to Benefit within LPL Financial, The Andersons, Del Frisco’s Restaurant Group, United Fire Group, Reata Pharmaceuticals, and Federal Agricultural Mortgage — Research Highlights Growth, Revenue, and Consolidated Results – Nasdaq” published on February 05, 2019, published: “Reata Breaks Out – Seeking Alpha” on July 25, 2018. More interesting news about Reata Pharmaceuticals, Inc. (NASDAQ:RETA) were released by: and their article: “Reata Pharma: This TPT Watchlist Stock Is Doing Pretty Well – Seeking Alpha” published on June 18, 2018 as well as‘s news article titled: “Reata Pharmaceuticals: Prospect In Pulmonary Arterial Hypertension – Seeking Alpha” with publication date: January 14, 2019.

The stock increased 2.02% or $1.75 during the last trading session, reaching $88.07. About 93,645 shares traded. Reata Pharmaceuticals, Inc. (RETA) has risen 127.24% since February 20, 2018 and is uptrending. It has outperformed by 127.24% the S&P500. Some Historical RETA News: 11/04/2018 – Reata Provides Update on the Phase 2 Portion of the CARDINAL Study of Bardoxolone Methyl in Patients With Alport Syndrome; 24/04/2018 – Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone in the Treatment of Friedreich’s Ataxia and Other Severe Neurological Diseases; 29/03/2018 – Reata Announces That Kyowa Hakko Kirin Received SAKIGAKE Priority Review Designation for Bardoxolone Methyl in Japan; 20/03/2018 – Report: Developing Opportunities within Super Micro Computer, Post, Reata Pharmaceuticals, Landstar System, Central Garden & Pe; 11/04/2018 – REATA PHARMACEUTICALS – ADVERSE EVENTS HAVE BEEN GENERALLY MILD TO MODERATE IN SEVERITY, NO DRUG-RELATED SERIOUS ADVERSE EVENTS BEEN REPORTED IN TRIAL; 08/05/2018 – Reata Pharmaceuticals at Deutsche Bank Conference Tomorrow; 10/04/2018 – Reata Pharmaceuticals at Deutsche Bank Conference May 9; 22/03/2018 – REATA REPORTS POSITIVE TOP-LINE DATA FOR TREATMENT OF PH-ILD WI; 24/04/2018 – Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone in the Treatment of Friedreich’s Ataxia and Other Severe Neurological Diseases; 11/04/2018 – REATA PHARMACEUTICALS INC RETA.O – BARDOXOLONE CONTINUES TO BE WELL-TOLERATED IN ALPORT SYNDROME PATIENTS

AutoWeb, Inc. operates as an automotive marketing services firm in the United States. The company has market cap of $44.43 million. It assists automotive retail dealers and manufacturers to market and sell new and used vehicles to clients through its programs. It currently has negative earnings. The companyÂ’s products include new vehicle lead program, which allows clients to submit requests for pricing and availability of specific makes and models; and used vehicle lead program, as well as finance leads program, which provides vehicle financing and other services from dealers or financial institutions.

AutoWeb, Inc. (NASDAQ:AUTO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.